Table 3.
Investigations for tuberculosis disease in the active case-finding pilot study
|
Initial screening |
6-week follow-up |
20-week follow-up |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sputum sample | Face-mask sample | Sputum sample | Face-mask sample | Chest radiography | Bronchoalveolar lavage result | PET-CT | Outcome | Sputum sample | Face-mask sample* | PET-CT | Outcome | |
| 2 | − | + | − | + | − | − | − | Treatment withheld and observed | − | − | − | Alternative diagnosis made |
| 3 | − | + | + | + | − | + | + | Tuberculosis treatment commenced | − | − | − | Completed treatment |
| 7 | − | + | + | + | − | + | + | Tuberculosis treatment commenced | − | − | − | Completed treatment |
| 13 | − | + | + | + | − | − | + | Tuberculosis treatment commenced | − | − | − | Completed treatment |
| 17 | − | + | + | + | − | − | + | Tuberculosis treatment commenced | − | − | − | Completed treatment |
Investigations were done in five participants (patient IDs 2, 3, 7, 13, and 17) who were exclusively face-mask-positive. Sputum and face-mask samples were analysed using the Xpert MTB/RIF Ultra platform.
*
Face-mask samples at 20-week follow-up were treated with propidium monoazide before Xpert MTB/RIF Ultra analysis.